New drug combo aims to tackle tough lymphoma
NCT ID NCT05053659
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing the safety and correct dose of combining two cancer drugs, loncastuximab tesirine and venetoclax, for people with non-Hodgkin lymphoma that has come back or stopped responding to treatment. About 23 adults will participate. The goal is to find a safe dose and see if the combination helps shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center
Cleveland, Ohio, 44195, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New combo therapy shows promise for tough lymphoma cases
- Double-Barreled attack: stem cell transplant plus CAR-T shows promise for Hard-to-Treat lymphoma
- Supercharged immune cells take on tough lymphoma
- Triple-Target CAR T-Cells offer new hope for tough blood cancers
- Supercharged immune cells take on tough B-Cell cancers in early trial
- Can a weekly drug combo outsmart resistant lymphoma?